PL3541185T3 - Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu - Google Patents

Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu

Info

Publication number
PL3541185T3
PL3541185T3 PL17871457.2T PL17871457T PL3541185T3 PL 3541185 T3 PL3541185 T3 PL 3541185T3 PL 17871457 T PL17871457 T PL 17871457T PL 3541185 T3 PL3541185 T3 PL 3541185T3
Authority
PL
Poland
Prior art keywords
hydroxybenzylamine
prevention
treatment
pulmonary hypertension
hypertension
Prior art date
Application number
PL17871457.2T
Other languages
English (en)
Polish (pl)
Inventor
Joshua P. Fessel
L. Jackson Roberts
James West
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of PL3541185T3 publication Critical patent/PL3541185T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17871457.2T 2016-11-15 2017-11-15 Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu PL3541185T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (1)

Publication Number Publication Date
PL3541185T3 true PL3541185T3 (pl) 2024-08-12

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17871457.2T PL3541185T3 (pl) 2016-11-15 2017-11-15 Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu

Country Status (9)

Country Link
US (2) US20190314302A1 (enExample)
EP (2) EP3541185B1 (enExample)
JP (1) JP7383285B2 (enExample)
CN (1) CN110177463B (enExample)
AU (1) AU2017362328B2 (enExample)
ES (1) ES2981715T3 (enExample)
HU (1) HUE067036T2 (enExample)
PL (1) PL3541185T3 (enExample)
WO (1) WO2018093936A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
AU2020210888A1 (en) 2019-01-25 2021-08-19 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
JP2023512225A (ja) * 2020-01-27 2023-03-24 ヴァンダービルト ユニバーシティー ミトコンドリア標的イソケタール／イソレブグランジンスカベンジャー及びその使用
WO2022081777A1 (en) * 2020-10-13 2022-04-21 Vanderbilt University Method of preventing kidney injury disruption of intestinal lymphatics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520422A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
JP5132109B2 (ja) * 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
CN101677992A (zh) * 2006-11-13 2010-03-24 M·F·麦卡蒂 抑制nadph氧化酶活性的组合物
US8314015B2 (en) * 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension
EP2731597B1 (en) * 2011-07-12 2023-12-20 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
WO2013142303A1 (en) * 2012-03-19 2013-09-26 Lycera Corporation Methods and compositions for detecting immune system activation
US20170056381A1 (en) * 2014-02-20 2017-03-02 Nanometics Llc Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Also Published As

Publication number Publication date
AU2017362328A1 (en) 2019-06-27
US20190314302A1 (en) 2019-10-17
EP3541185C0 (en) 2024-04-24
ES2981715T3 (es) 2024-10-10
EP3541185A1 (en) 2019-09-25
EP3541185A4 (en) 2020-06-24
AU2017362328B2 (en) 2022-03-31
EP4385576A2 (en) 2024-06-19
EP3541185B1 (en) 2024-04-24
JP2019536778A (ja) 2019-12-19
CN110177463A (zh) 2019-08-27
US20250381155A1 (en) 2025-12-18
EP4385576A3 (en) 2024-09-04
JP7383285B2 (ja) 2023-11-20
CN110177463B (zh) 2022-03-08
HUE067036T2 (hu) 2024-09-28
WO2018093936A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
IL259751B (en) Polycyclic compounds and their use in the treatment of immune disorders
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
LT4014976T (lt) Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
ZA201901055B (en) Treatment and prevention of sleep disorders
PL3484585T5 (pl) Zastosowanie probiotyków w leczeniu i/lub zapobieganiu atopowemu zapaleniu skóry
ZA201704726B (en) Peptides and their use in the treatment of skin
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
PL3541185T3 (pl) Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
HUE058749T2 (hu) Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra
HUE050456T2 (hu) Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra
PL3197556T3 (pl) KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
GB2546965B (en) Improvements in and relating to the treatment of arthrofibrosis
PT3408287T (pt) Gdf15 em glaucoma e respetivos métodos de utilização
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
IL265242B (en) Compounds for the treatment of hypertension and/or fibrosis
SG11201802955VA (en) Peptides of use in the preventive and curative treatment of alopecia
TH1801002163A (th) เพปไทด์เพื่อใช้ในการรักษาป้องกันและเยียวยาภาวะศีรษะล้าน
PL3152193T3 (pl) Pochodne tetrahydroizochinolinonu i ich zastosowanie do hamowania białka hsp70
PL3280430T3 (pl) Peptyd QBP1 do stosowania w zapobieganiu lub leczeniu zespołu stresu pourazowego, ostrego zaburzenia stresowego oraz ogólnego zespołu adaptacyjnego
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer